Physician profile
Phyllis Chang
NPI 1316058266
$3,553.32
in general payments reported to CMS, 2019-2025
26 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $853 · 2020: $82.08 · 2021: $154 · 2022: $666 · 2023: $911 · 2024: $765 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,799.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,798.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,102.74 | 2019-2024 | Skyrizi, Rinvoq, Mavyret |
| Janssen Biotech, INC. | $283.16 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $243.20 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $242.22 | 2019-2024 | Xifaxan, Plenvu, Trulance |
| Pfizer INC. | $240.07 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $211.86 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $173.88 | 2019-2024 | Gattex, Entyvio |
| Madrigal Pharmaceuticals | $153.40 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $140.07 | 2023 | Ocaliva |
| E.R. Squibb & Sons, L.L.C. | $122.88 | 2023 | Zeposia |
| Celgene Corporation | $122.60 | 2022-2024 | Zeposia |
| Merck Sharp & Dohme LLC | $89.59 | 2019-2024 | Dificid |
| Braintree Laboratories, INC. | $63.93 | 2021-2023 | Sutab, Suflave |
| Qol Medical, LLC | $48.27 | 2021-2023 | Sucraid |
| Nestle Healthcare Nutrition INC. | $47.08 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $36.07 | 2023-2024 | |
| Aimmune Therapeutics, INC. | $33.70 | 2024 | |
| Phathom Pharmaceuticals, INC. | $31.43 | 2024 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $29.62 | 2024 | Dupixent |
| Lilly USA, LLC | $27.31 | 2024 | Omvoh |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.48 | 2023 | |
| Shield Therapeutics INC | $20.29 | 2022 | |
| Alnylam Pharmaceuticals INC. | $19.92 | 2023 | Onpattro |
| Fresenius Kabi USA, LLC | $19.16 | 2023 | Idacio |
| Ipsen Biopharmaceuticals, INC | $14.27 | 2024 | Iqirvo |
| Redhill Biopharma INC. | $14.12 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Phyllis Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.